Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
azd4547 (56) 56
index medicus (43) 43
humans (37) 37
cancer (31) 31
oncology (28) 28
gene amplification (17) 17
fibroblast growth factors (15) 15
expression (14) 14
cell line, tumor (13) 13
fgfr (12) 12
selective inhibitor (12) 12
animals (11) 11
antineoplastic agents - pharmacology (11) 11
cell proliferation - drug effects (11) 11
fibroblasts (11) 11
growth factors (11) 11
protein kinase inhibitors - pharmacology (11) 11
biochemistry & molecular biology (10) 10
fibroblast growth factor receptors (10) 10
gene expression (10) 10
kinases (10) 10
mutation (10) 10
mutations (10) 10
receptors, fibroblast growth factor - antagonists & inhibitors (10) 10
cell biology (9) 9
female (9) 9
fibroblast growth factor (9) 9
fibroblast growth factor receptor (9) 9
gastric cancer (9) 9
growth (9) 9
health aspects (9) 9
male (9) 9
potent (9) 9
pyrazoles - pharmacology (9) 9
receptor, fibroblast growth factor, type 1 - genetics (9) 9
receptor, fibroblast growth factor, type 1 - metabolism (9) 9
amplification (8) 8
benzamides - pharmacology (8) 8
carcinoma (8) 8
care and treatment (8) 8
chemistry, medicinal (8) 8
inhibitor (8) 8
piperazines - pharmacology (8) 8
sensitivity (8) 8
activation (7) 7
analysis (7) 7
article (7) 7
breast cancer (7) 7
development and progression (7) 7
fgfr1 (7) 7
lung cancer (7) 7
metastasis (7) 7
mice (7) 7
middle aged (7) 7
molecular structure (7) 7
receptor, fibroblast growth factor, type 2 - metabolism (7) 7
tumors (7) 7
tyrosine (7) 7
aged (6) 6
angiogenesis (6) 6
antineoplastic agents - chemistry (6) 6
apoptosis (6) 6
cancer therapies (6) 6
carcinoma, squamous cell - genetics (6) 6
chemotherapy (6) 6
dose-response relationship, drug (6) 6
family (6) 6
inhibitors (6) 6
lung neoplasms - drug therapy (6) 6
lung neoplasms - genetics (6) 6
medicine & public health (6) 6
protein kinase inhibitors - chemistry (6) 6
receptor, fibroblast growth factor, type 1 - antagonists & inhibitors (6) 6
stomach cancer (6) 6
studies (6) 6
tyrosine kinase (6) 6
xenograft model antitumor assays (6) 6
antineoplastic agents - therapeutic use (5) 5
cell proliferation (5) 5
cells (5) 5
drug resistance (5) 5
drug screening assays, antitumor (5) 5
fgfr2 (5) 5
fibroblast growth factor receptor 1 (5) 5
genetic aspects (5) 5
growth-factor receptor (5) 5
in situ hybridization, fluorescence (5) 5
inhibitor azd4547 (5) 5
phosphorylation (5) 5
ponatinib (5) 5
proteins (5) 5
receptor, fibroblast growth factor, type 2 - antagonists & inhibitors (5) 5
receptor, fibroblast growth factor, type 2 - genetics (5) 5
receptors, fibroblast growth factor - metabolism (5) 5
research (5) 5
resistance (5) 5
selectivity (5) 5
signal transduction (5) 5
signal transduction - drug effects (5) 5
structure-activity relationship (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text A Phase 1b Open Label Multicentre Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers
by Paik, Paul K and Shen, Ronglai and Berger, Michael F and Ferry, David and Soria, Jean-Charles and Mathewson, Alastair and Rooney, Claire and Smith, Neil R and Cullberg, Marie and Kilgour, Elaine and Landers, Donal and Frewer, Paul and Brooks, Nigel and Andre, Fabrice
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 9/2017, Volume 23, Issue 18, pp. 5366 - 5373
AZD4547 | squamous lung cancer | FGFR1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Upregulation of Fibroblast Growth Factors Caused by Heart and Neural Crest Derivatives Expressed 2 Suppression in Endometriotic Cells: A Possible Therapeutic Target in Endometriosis
by Kato, Nao and Iwase, Akira and Ishida, Chiharu and Nagai, Takashi and Mori, Masahiko and Bayasula and Nakamura, Tomoko and Osuka, Satoko and Ganiyeva, Umida and Qin, Ying and Miki, Rika and Kikkawa, Fumitaka
Reproductive Sciences, ISSN 1933-7191, 7/2019, Volume 26, Issue 7, pp. 979 - 987
Several features exist that distinguish endometriotic cells from eutopic endometrial cells. Progesterone resistance is one of the main distinguishing features,... 
AZD4547 | endometriosis | FGF | HAND2 | PROGESTERONE | MECHANISMS | PATHOPHYSIOLOGY | OBSTETRICS & GYNECOLOGY | WOMEN | INHIBITOR AZD4547 | REPRODUCTIVE BIOLOGY | GENES | STROMAL CELLS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification
by Van Cutsem, E and Bang, Y.-J and Mansoor, W and Petty, R.D and Chao, Y and Cunningham, D and Ferry, D.R and Smith, N.R and Frewer, P and Ratnayake, J and Stockman, P.K and Landers, D and Kilgour, E
Annals of Oncology, ISSN 0923-7534, 06/2017, Volume 28, Issue 6, pp. 1316 - 1324
Background: Approximately 5%-10% of gastric cancers have a fibroblast growth factor receptor-2 (FGFR2) gene amplification. AZD4547 is a selective FGFR-1, 2, 3... 
AZD4547 | Fibroblast growth factor receptor | Gastric cancer | Clinical efficacy | Fluorescence in situ hybridization | gastric cancer | PHASE-III | CANCER | CHEMOTHERAPY | fluorescence in situ hybridization | TRIAL | SUPPORTIVE CARE | INHIBITOR AZD4547 | ONCOLOGY | fibroblast growth factor receptor | PHOSPHATE HOMEOSTASIS | IRINOTECAN | clinical efficacy | PLUS | Piperazines - administration & dosage | Stomach Neoplasms - genetics | Humans | Paclitaxel - adverse effects | Antineoplastic Agents - administration & dosage | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Piperazines - adverse effects | Disease-Free Survival | Benzamides - administration & dosage | Pyrazoles - administration & dosage | Gene Amplification | Antineoplastic Agents - adverse effects | Cell Line, Tumor | Adenocarcinoma - genetics | Paclitaxel - administration & dosage | Benzamides - adverse effects | Receptor, Fibroblast Growth Factor, Type 2 - genetics | Pyrazoles - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors
by Wang, Yuming and Li, Lijun and Fan, Jun and Dai, Yang and Jiang, Alan and Geng, Meiyu and Ai, Jing and Duan, Wenhu
Journal of Medicinal Chemistry, ISSN 0022-2623, 10/2018, Volume 61, Issue 20, pp. 9085 - 9104
Fibroblast growth factor receptors (FGFR1–4) are promising therapeutic targets in many cancers. With the resurgence of interest in irreversible inhibitors,... 
CH5183284/DEBIO 1347 | AZD4547 | SELECTIVE INHIBITOR | DESIGN | CHEMISTRY, MEDICINAL | COVALENT INHIBITORS | JNJ-42756493 | OVERCOME RESISTANCE | DERIVATIVES | EGFR | STRATEGIES
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Lung Master Protocol (Lung-MAP) - A biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400
by Herbst, Roy S and Gandara, David R and Hirsch, Fred R and Redman, Mary W and LeBlanc, Michael and Mack, Philip C and Schwartz, Lawrence H and Vokes, Everett and Ramalingam, Suresh S and Bradley, Jeffrey D and Sparks, Dana and Zhou, Yang and Miwa, Crystal and Miller, Vincent A and Yelensky, Roman and Li, Yali and Allen, Jeff D and Sigal, Ellen V and Wholley, David and Sigman, Caroline C and Blumenthal, Gideon M and Malik, Shakun and Kelloff, Gary J and Abrams, Jeffrey S and Blanke, Charles D and Papadimitrakopoulou, Vassiliki A
Clinical Cancer Research, ISSN 1078-0432, 04/2015, Volume 21, Issue 7, pp. 1514 - 1524
The Lung Master Protocol (Lung-MAP, S1400) is a ground-breaking clinical trial designed to advance the efficient development of targeted therapies for squamous... 
AZD4547 | PALBOCICLIB | SELECTIVE INHIBITOR | POTENT | GENOMICS | BAR | ONCOLOGY | CLINICAL-TRIALS | ALECTINIB | TARGETS | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Carcinoma, Squamous Cell - drug therapy | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Squamous Cell - genetics | Humans | Antineoplastic Agents - therapeutic use | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Research Design | Precision Medicine - methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy
by Kim, SM and Kim, H and Yun, MR and Kang, HN and Pyo, KH and Park, HJ and Lee, JM and Choi, HM and Ellinghaus, P and Ocker, M and Paik, S and Kim, HR and Cho, BC
ONCOGENESIS, ISSN 2157-9024, 07/2016, Volume 5, Issue 7, pp. e241 - e241
Aberrant fibroblast growth factor receptor (FGFR) activation/expression is a common feature in lung cancer (LC). In this study, we evaluated the antitumor... 
AZD4547 | AMPLIFICATION | ONCOLOGY | SQUAMOUS-CELL CARCINOMA | SENSITIVITY | INHIBITOR | GEFITINIB RESISTANCE | EXPRESSION | RECEPTOR TYROSINE KINASE | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region
by Fairhurst, Robin A and Knoepfel, Thomas and Leblanc, Catherine and Buschmann, Nicole and Gaul, Christoph and Blank, Jutta and Galuba, Inga and Trappe, Jörg and Zou, Chao and Voshol, Johannes and Genick, Christine and Brunet-Lefeuvre, Peggy and Bitsch, Francis and Graus-Porta, Diana and Furet, Pascal
MedChemComm, ISSN 2040-2503, 2017, Volume 8, Issue 8, pp. 1604 - 1613
A diverse range of selective FGFR4 inhibitor hit series were identified using unbiased screening approaches and by the modification of known kinase inhibitor... 
MEDICINAL CHEMISTRY | AZD4547 | POTENT | CHEMISTRY, MEDICINAL | PATHWAY | TYROSINE KINASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | FGFR4 INHIBITORS | THERAPIES | CANCER | DISCOVERY | FAMILY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Upregulation of EphB3 in gastric cancer with acquired resistance to a FGFR inhibitor
by Lee, Dae-Hee and Lee, Suk-young and Na, Yoo Jin and Jeong, Yoon A and Kim, Jung Lim and Oh, Sang Cheul
International Journal of Biochemistry and Cell Biology, ISSN 1357-2725, 09/2018, Volume 102, pp. 128 - 137
Amplification of has been regarded as a druggable target in gastric cancer (GC). Despite known potential of AZD4547, a selective inhibitor of FGFR 1–3, to... 
Resistance | mTOR | FGFR inhibitor | Gastric cancer | EphB3 | SIGNALING PATHWAYS | ADENOCARCINOMA | BIOCHEMISTRY & MOLECULAR BIOLOGY | KINASE | CELL BIOLOGY | EPITHELIAL-MESENCHYMAL TRANSITION | CELL LUNG-CANCER | AZD4547 | GROWTH-FACTOR RECEPTOR | COLORECTAL-CANCER | GENE AMPLIFICATION | PROGNOSTIC-SIGNIFICANCE | Tyrosine | Cellular signal transduction | Fibroblast growth factors | Stomach cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer
by Cihoric, N and Savic, S and Schneider, S and Ackermann, I and Bichsel-Naef, M and Schmid, R.A and Lardinois, D and Gugger, M and Bubendorf, L and Zlobec, I and Tapia, C
British Journal of Cancer, ISSN 0007-0920, 06/2014, Volume 110, Issue 12, pp. 2914 - 2922
Background: Recently, fibroblast growth factor receptor 1 (FGFR1) was discovered in squamous cell carcinomas (SCC) of the lung with FGFR1 amplification... 
Amplification | Fluorescence in situ hybridisation | Squamous cell carcinoma | Prognosis | NSCLC | FGFR1 | ACTIVATION | GEFITINIB | prognosis | AZD4547 | amplification | ONCOLOGY | fluorescence it situ hybridisation | CARCINOMA | EXPRESSION | IN-SITU | squamous cell carcinoma | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Lung Neoplasms - mortality | Tissue Array Analysis | Carcinoma, Squamous Cell - genetics | Humans | Middle Aged | In Situ Hybridization, Fluorescence | Male | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Carcinoma, Squamous Cell - mortality | Gene Amplification | Aged, 80 and over | Adult | Female | Neoplasm Recurrence, Local - genetics | Aged | Molecular Diagnostics | fluorescence in situ hybridisation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Next-generation sequencing of stage IV squamous cell lung cancers reveals an association of PI3K aberrations and evidence of clonal heterogeneity in patients with brain metastases
by Paik, Paul K and Shen, Ronglai and Won, Helen and Rekhtman, Natasha and Wang, Lu and Sima, Camelia S and Arora, Arshi and Seshan, Venkatraman and Ladanyi, Marc and Berger, Michael F and Kris, Mark G
Cancer Discovery, ISSN 2159-8274, 06/2015, Volume 5, Issue 6, pp. 610 - 621
Large-scale genomic characterization of squamous cell lung cancers (SQCLC) has revealed several putative oncogenic drivers. There are, however, little data to... 
SURVIVAL | AZD4547 | AMPLIFICATION | ONCOLOGY | PATHWAY | ADENOCARCINOMA | COPY NUMBER | SENSITIVITY | MUTATIONS | CARCINOMA | EXPRESSION | Lung Neoplasms - mortality | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Receptor, Fibroblast Growth Factor, Type 1 - metabolism | Lung Neoplasms - pathology | Male | Phosphatidylinositol 3-Kinases - metabolism | Receptor, Fibroblast Growth Factor, Type 1 - genetics | DNA Copy Number Variations | Genetic Variation | Brain Neoplasms - secondary | Neoplasm Metastasis | Carcinoma, Squamous Cell - mortality | DNA Mutational Analysis | Aged, 80 and over | Female | Lung Neoplasms - genetics | PTEN Phosphohydrolase - genetics | Gene Expression | PTEN Phosphohydrolase - deficiency | Serpins - genetics | Signal Transduction | Risk Factors | Kaplan-Meier Estimate | Carcinoma, Squamous Cell - therapy | Genotype | Lung Neoplasms - therapy | Phosphatidylinositol 3-Kinases - genetics | Gene Amplification | Aged | High-Throughput Nucleotide Sequencing | Mutation | Neoplasm Staging | Clonal Evolution | brain metastasis | squamous cell lung cancer | PI3K | FGFR1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text High amplification of FGFR1 gene is a delayed poor prognostic factor in early stage ESCC patients
by Song, Qi and Liu, Yalan and Jiang, Dongxian and Wang, Haixing and Huang, Jie and Xu, Yifan and Sujie, Akesu and Zeng, Haiying and Xu, Chen and Hou, Yingyong
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 43, pp. 74539 - 74553
Amplification of the fibroblast growth factor receptor 1 (FGFR1) is believed to predict response to FGFR inhibitors. The aim of this study was to investigate... 
Clinical stage | Disease free survival time | FGFR1 high amplification | ESCC | Prognostic marker | SURVIVAL | PROTEIN | LANDSCAPE | disease free survival time | clinical stage | CANCER | CELL BIOLOGY | AZD4547 | prognostic marker | SQUAMOUS-CELL CARCINOMA | EXPRESSION
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Sulfated polysaccharide of Sepiella maindroni ink targets Akt and overcomes resistance to the FGFR inhibitor AZD4547 in bladder cancer
by Shan, LP and Liu, W and Zhan, YH
AGING-US, ISSN 1945-4589, 09/2019, Volume 11, Issue 18, pp. 7780 - 7795
Rapid appearance of resistance to fibroblast growth factor receptor (FGFR) inhibitors hampers targeted regimens in bladder cancer. In the present study, we... 
MIGRATION | SIGNALING PATHWAYS | COMPREHENSIVE MOLECULAR CHARACTERIZATION | SENSITIVITY | CELL BIOLOGY | GERIATRICS & GERONTOLOGY | AZD4547 | INVASION | xenograft | bladder cancer | GROWTH | sulfated polysaccharide of Sepiella maindroni ink | CARCINOMA | EXPRESSION | FGFR therapy resistance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma
by Kim, H.R and Kang, H.N and Shim, H.S and Kim, E.Y and Kim, J and Kim, D.J and Lee, J.G and Lee, C.Y and Hong, M.H and Kim, S.-M and Kim, H and Pyo, K.-H and Yun, M.R and Park, H.J and Han, J.Y and Youn, H.A and Ahn, M.-J and Paik, S and Kim, T.-M and Cho, B.C
Annals of Oncology, ISSN 0923-7534, 06/2017, Volume 28, Issue 6, pp. 1250 - 1259
Background: We conducted co-clinical trials in patient-derived xenograft (PDX) models to identify predictive biomarkers for the multikinase inhibitor dovitinib... 
Biomarker | Dovitinib | Squamous cell lung cancer | Fibroblast growth factor receptor | Patient-derived xenograft | SURVIVAL | XENOGRAFT MODELS | NUMBER | PANEL | dovitinib | squamous cell lung cancer | biomarker | CANCER | AZD4547 | AMPLIFICATION | ONCOLOGY | fibroblast growth factor receptor | patient-derived xenograft | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Signal Transduction | Carcinoma, Squamous Cell - genetics | Humans | Receptors, Fibroblast Growth Factor - antagonists & inhibitors | Clinical Trials as Topic | Biomarkers - blood | Whole Exome Sequencing | Carcinoma, Squamous Cell - drug therapy | Quinolones - therapeutic use | Receptors, Fibroblast Growth Factor - metabolism | Mutation | Benzimidazoles - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Establishment of a New Scirrhous Gastric Cancer Cell Line with FGFR2 Overexpression, OCUM-14
by Okuno, Tomohisa and Yashiro, Masakazu and Masuda, Go and Togano, Shingo and Kuroda, Kenji and Miki, Yuichiro and Hirakawa, Kosei and Ohsawa, Masahiko and Wanibuchi, Hideki and Ohira, Masaichi
Annals of Surgical Oncology, ISSN 1068-9265, 4/2019, Volume 26, Issue 4, pp. 1093 - 1102
The prognosis of scirrhous gastric carcinoma (SGC), which is characterized by rapid infiltration and proliferation of cancer cells accompanied by extensive... 
Oncology | Medicine & Public Health | Surgical Oncology | Surgery | AZD4547 | SURGERY | FACTOR RECEPTOR INHIBITOR | SELECTIVE INHIBITOR | KERATINOCYTE GROWTH-FACTOR | ONCOLOGY | SAFETY | GENE AMPLIFICATION | MYOFIBROBLASTS | K-SAM | PHASE-I | CARCINOMA | Fibroblast growth factors | Epidermal growth factor | Stomach cancer | Analysis | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Therapeutics targeting angiogenesis: Genetics and epigenetics, extracellular miRNAs and signaling networks (Review)
by Katoh, Masaru
International Journal of Molecular Medicine, ISSN 1107-3756, 10/2013, Volume 32, Issue 4, pp. 763 - 767
Angiogenesis is a process of neovascular formation from pre-existing blood vessels, which consists of sequential steps for vascular destabilization, angiogenic... 
Dovitinib | Lung cancer | Colorectal cancer | Breast cancer | Ponatinib | Vascular medicine | Bevacizumab | AZD4547 | Sunitinib | Sorafenib | Chitosan | Gastric cancer | Field cancerization | Poly(lactic-co-glycolic acid) | sunitinib | VASCULAR DEVELOPMENT | MEDICINE, RESEARCH & EXPERIMENTAL | chitosan | CELLS | vascular medicine | ANTI-VEGF | colorectal cancer | sorafenib | gastric cancer | breast cancer | dovitinib | OVARIAN-CANCER | DELIVERY | lung cancer | BREAST-CANCER | field cancerization | THERAPY | DISEASE | bevacizumab | ponatinib | poly(lactic-co-glycolic acid) | ENDOTHELIAL GROWTH-FACTOR | Cell Proliferation | Epigenesis, Genetic | Humans | MicroRNAs - metabolism | Vascular Endothelial Growth Factor A - genetics | Antibodies, Monoclonal, Humanized - genetics | Fibroblast Growth Factor 4 - genetics | Neoplasms - therapy | Neoplasms - genetics | Angiogenesis Inhibitors - therapeutic use | Fibroblast Growth Factor 2 - metabolism | Fibroblast Growth Factor 4 - metabolism | Neovascularization, Pathologic - therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Signal Transduction | Endothelial Cells - metabolism | Vascular Endothelial Growth Factor A - therapeutic use | Genotype | Fibroblast Growth Factor 2 - genetics | Macular Degeneration - genetics | Macular Degeneration - therapy | Neovascularization, Pathologic - genetics | MicroRNAs - genetics | Neoplasms - pathology | Macular Degeneration - pathology
Journal Article
Details down arrow
16. Full Text An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors
by Cheng, Weiyan and Wang, Mixiang and Tian, Xin and Zhang, Xiaojian
European Journal of Medicinal Chemistry, ISSN 0223-5234, 01/2017, Volume 126, pp. 476 - 490
The fibroblast growth factor receptor (FGFR) family receptor tyrosine kinase (RTK) includes four structurally related members, termed as FGFR1, FGFR2, FGFR3,... 
DFG-in/out | Pharmacological activity | Irreversible | FGFR | Small molecule inhibitor | Crystal structure | DOMAIN | CHEMISTRY, MEDICINAL | SENSITIVITY | NVP-BGJ398 | ENDOMETRIAL CANCER | FAMILY | AZD4547 | GROWTH-FACTOR RECEPTOR | SELECTIVE INHIBITOR | MUTATION | OPPORTUNITY | Small Molecule Libraries - chemistry | Small Molecule Libraries - pharmacology | Protein Kinase Inhibitors - chemistry | Humans | Protein Binding | Protein Kinase Inhibitors - pharmacology | Small Molecule Libraries - metabolism | Receptor Protein-Tyrosine Kinases - metabolism | Protein Kinase Inhibitors - metabolism | Tyrosine | Analysis | Pharmacy | Crystals | Phenols | Drugstores | Fibroblast growth factors | Structure | Phosphotransferases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Structure-based discovery of a series of 5H-pyrrolo[2, 3-b]pyrazine FGFR kinase inhibitors
by Jiang, Alan and Liu, Qiufeng and Wang, Ruifeng and Wei, Peng and Dai, Yang and Wang, Xin and Xu, Yechun and Ma, Yuchi and Ai, Jing and Shen, Jingkang and Ding, Jian and Xiong, Bing
Molecules, ISSN 1420-3049, 2018, Volume 23, Issue 3, p. 698
Fibroblast growth factor receptors (FGFRs), a subfamily of receptor tyrosine kinases, are aberrant in various cancer types, and considered to be promising... 
Pyrrolo[2,3-b]pyrazine | FGFR | Kinase inhibitor | Cancer | CH5183284/DEBIO 1347 | AZD4547 | kinase inhibitor | SELECTIVE INHIBITOR | POTENT | pyrrolo[2,3-b]pyrazine | BIOCHEMISTRY & MOLECULAR BIOLOGY | cancer | TARGETING FGFR | CHEMISTRY, MULTIDISCIPLINARY | Tyrosine | Fibroblast growth factor | Hepatocyte growth factor | Cyclin-dependent kinases | Growth factor receptors | Kinases | c-Met protein | Receptors | Inhibitors | Pyrazine | Growth factors | Fibroblast growth factor receptor 1 | Crystal structure | Fibroblast growth factor receptors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Innovative Clinical Trials: The LUNG‐MAP Study
by Steuer, CE and Papadimitrakopoulou, V and Herbst, RS and Redman, MW and Hirsch, FR and Mack, PC and Ramalingam, SS and Gandara, DR
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 05/2015, Volume 97, Issue 5, pp. 488 - 491
Although the proportion of patients with squamous cell carcinoma of the lung has declined over the last two decades, the disease is still fatal for tens of... 
AZD4547 | 1ST-LINE TREATMENT | THERAPY | PHASE-II | PHARMACOLOGY & PHARMACY | MUTATIONS | INHIBITOR | CANCER | CHEMOTHERAPY | EGFR | Lung Neoplasms - drug therapy | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Genomics | Humans | Lung Neoplasms - metabolism | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Clinical Trials, Phase III as Topic - methods | Carcinoma, Non-Small-Cell Lung - secondary | Biomarkers, Tumor - metabolism | Precision Medicine | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Phenotype | Carcinoma, Squamous Cell - drug therapy | Signal Transduction - drug effects | Carcinoma, Squamous Cell - secondary | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Clinical Trials, Phase II as Topic - methods | Research Design | Squamous cell carcinoma | Usage | Oncology, Experimental | Clinical trials | Research | Drug therapy | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights